Latest Safety News

Alliance Aviation Services posted a statutory loss of $90.9 million in FY2026, driven by a $164.8 million impairment on its Fokker fleet, while underlying profit remained within guidance. The company is realigning around core FIFO operations, fleet renewal, and cost discipline, supported by a $40 million equity raise and revised Qantas wet lease terms.

Ora Banda Mining delivered record FY26 results with a 53% jump in gold production and doubled revenue to $807.5 million, underpinning its DRIVE to 300 growth strategy targeting 300,000 ounces annually by FY29.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

Imagion Biosystems has signed key CRO work orders and completed manufacturing of its MagSense HER2 Imaging Agent, advancing its Phase 1b/2 clinical trial targeting HER2+ breast cancer. Trial initiation is underway with seven prospective sites, including contract talks with the first US clinical site.

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

Nickel Industries surged to a US$74 million profit in H1 2026, driven by higher nickel prices, expanded mining quotas, and strategic HPAL investments including first nickel cathode production at ENC.

MotorCycle Holdings Limited (ASX:MTO) posted a 21.3% revenue increase and 34% net profit growth for FY26, driven by organic sales and acquisitions. The company declared a higher final dividend and released its inaugural climate-related financial disclosures.

Mastermyne Group Limited (ASX:MYE) delivered a robust FY26 with revenue up 13% to $237.7 million and underlying profit before tax surging 148% to $15.7 million, supported by contract wins and a record order book.

Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a trial for RV-01, a radiopharmaceutical targeting B7-H3 expressing solid tumors, marking a key dose escalation milestone.

Prescient Therapeutics (ASX:PTX) has opened a $7 million Share Purchase Plan at a significant discount to advance its lead cancer therapy PTX-100 beyond a pivotal Dose Optimisation Committee review in late 2026.

Paladin Energy Ltd (ASX:PDN) reversed prior losses with a net profit of US$5.3 million in FY2026, driven by a strong ramp-up of uranium production at Namibia's Langer Heinrich Mine and regulatory progress at its Canadian Patterson Lake South Project.

Advanced Braking Technology Ltd (ASX: ABV) posted a 22.7% revenue increase to $23.48 million and a 16.6% rise in net profit after tax to $2.075 million for FY26, driven by international expansion and advances in autonomous braking technology.